Mercury Therapeutics Licenses Dartmouth Protein Kinase IP to Millipore | GenomeWeb

NEW YORK (GenomeWeb News) - Mercury Therapeutics said yesterday that it has granted Millipore exclusive worldwide rights to human AMP-activated protein kinase in the field of research products and services.

The AMPK patent was originally licensed by Mercury Therapeutics in 2000 from Dartmouth College. The patent is based on research by Dartmouth professor Lee Witters and his collaborator Bruce Kemp from the St. Vincent's Institute for Medical Research in Melbourne, Australia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.